Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience

Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience

Belantamab-mafodotin is an innovative and selective treatment for multi-refractory/relapsed multiple myeloma (MM) patients; however, available real-life experiences on efficacy and safety are limited. In this real-world multicentric retrospective study, we enrolled 28 MM patients treated in four Hem...

Full description

Bibliographic Details
Main Authors: Rossella Iula, Danilo De Novellis, Fabio Trastulli, Roberta Della Pepa, Raffaele Fontana, Angela Carobene, Maria Di Perna, Alessandro D’Ambrosio, Martina Romano, Aldo Leone, Laura De Fazio, Alfonso Fiumarella, Giuseppe Gaeta, Violetta Marafioti, Serafina Barbato, Salvatore Palmieri, Stefano Rocco, Bianca Serio, Catello Califano, Fabrizio Pane, Felicetto Ferrara, Valentina Giudice, Carmine Selleri, Lucio Catalano
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
anti-BCMA
multiple myeloma
refractory
multi-refractory
real life
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1026251/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1026251/full

Similar Items